ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal models"

  • Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting

    Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages

    Takuya Matsumoto1, Nobunori Takahashi1, Toshihisa Kojima1 and Naoki Ishiguro2, 1Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 2Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
  • Abstract Number: 1053 • 2015 ACR/ARHP Annual Meeting

    Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome

    Saba Nayar1, Joana Campos1, Christopher Buckley1, Rodger Allen2, W.A. Fahy2, Andrew Payne2 and Francesca Barone1, 1University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, 2UCB Pharma, Slough, United Kingdom

    Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by B cell hyper-activation and exocrine gland infiltration that results in loss of glandular function,…
  • Abstract Number: 2557 • 2015 ACR/ARHP Annual Meeting

    Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20

    Yue Sun, Wei Kong, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose: Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). Mesenchymal stem cells (MSC) present multiple immunosuppressive capacities and…
  • Abstract Number: 3192 • 2015 ACR/ARHP Annual Meeting

    KCa3.1 Ion Channel in the Pathogenesis of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not Develop CIA

    Siba Raychaudhuri1, Smriti K. Raychaudhuri2 and Heike Wulff3, 1Med/Rheumatology, Univ California Davis/VA Sacramento, Davis, CA, 2Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA, 3Pharmacology, UC Davis School of Medicine, Davis, CA

    Background/Purpose: KCa3.1 is a Ca2+-activated K+ channel that modulates Ca2+-dependent signaling processes such as activation and cellular proliferation. KCa3.1 is expressed in CCR7+ naïve and…
  • Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation

    Christian Goess1, Candace Graff2, Ting Ting Zhang2, Gregory Preston2, Richard McCarthy1, Matthew Perham1, Jacqueline Loud1, Christopher M. Harris1, Sara Murdock1, Erik Sampson3, Michael Hoemann4, Michael Friedman4, Robert Talanian3, Jeremy Edmunds4 and Andrew Long1, 1Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
  • Abstract Number: 2558 • 2015 ACR/ARHP Annual Meeting

    The Role of Leukocyte Associated Immunoglobulin-like Receptor-1 (LAIR-1) in Collagen-Induced Arthritis

    Seunghyun Kim1, John E. Coligan2, Jeoung-Eun Park3, John M. Stuart4, Andrew Kang5 and Linda Myers5, 1Rheumatology, University of Tennessee Health Science Center, Memphis, TN, 2NIH, Bethesda, MD, 3University of Tennessee, Memphis, TN, 4University of Tennessee/Veterans Affairs, Memphis, TN, 5University of Tennessee Health Science Center, Memphis, TN

    Background/Purpose: Several observations implicate a critical role for T cell dysregulation as a central problem in RA.  We present a method for suppressing T cell…
  • Abstract Number: 1123 • 2015 ACR/ARHP Annual Meeting

    Regulatory B Cells Regulate Skin and Lung Fibrosis and Immunological Abnormalities in a Topoisomerase I and Complete Freund’s Adjuvant-Induced Scleroderma Model Via an Antigen-Specific Manner

    Ayumi Yoshizaki1, Takashi Taniguchi1, Kouki Nakamura1, Ryosuke Saigusa1, Takashi Yamashita1, Takehiro Takahashi1, Tetsuo Toyama1, Yohei Ichimura1, Yoshihide Asano2 and Shinichi Sato1, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Immune cells play a critical role in systemic sclerosis (SSc). B cells have more functions than producing antibodies, including antigen-presentation, various cytokine production, and…
  • Abstract Number: 2559 • 2015 ACR/ARHP Annual Meeting

    PRO-Resolving Mediators Issued from Apoptotic CELL Efferocytosis (SUPERMAPO) Modulate Antigen Presenting CELL Properties Toward a Tolerogenic Profile: Efficacy in the Treatment of Collagen- Induced Arthritis

    Francis Bonnefoy1, Romain Vallion2, Mélanie Couturier3, Anna Daoui3, Eric Toussirot4 and Sylvain Perruche1, 1UMR1098 INSERM, EFS Bourgogne Franche Comté, Besançon, France, 2INSERM UMR 1098, EFS Bourgogne Franche Comté, Besançon, France, 3INSERM UMR1098, EFS Bourgogne Franche Comté, Besançon, France, 4Service de Rhumatologie, CHU J Minjoz, Besancon, France

    Background/Purpose: Pro-resolving mediators produced by macrophages eliminating apoptotic effector cells during the resolution of inflammation have been shown to stop inflammation, favor tissue repair and…
  • Abstract Number: 1173 • 2015 ACR/ARHP Annual Meeting

    G Protein Coupled Receptor Kinase 3 Regulation of Inflammatory Arthritis

    Matthew J. Billard1, Roman Timoshchenko2, D. Stephen Serafin2 and Teresa K. Tarrant3, 1Medicine, University of North Carolina, Chapel Hill, NC, 2Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 3Rheumatology, University of North Carolina, Chapel Hill, NC

    Background/Purpose:   Chemokine receptors are G Protein Coupled Receptor (GPCR) family members that direct cell migration, differentiation, and survival in inflammatory conditions, but neutralization strategies…
  • Abstract Number: 2560 • 2015 ACR/ARHP Annual Meeting

    The Mer Tyrosine Kinase Receptor Plays a Protective Role in Joint Inflammation By Mediating Efferocytosis

    Claire E.J. Waterborg1, Silke Beermann1, Miranda B. Bennink1, Carla V. Rothlin2, Greg Lemke3 and Fons A.J. van de Loo1, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, 3Molecular Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by a hyper-inflammatory response in synovial joints. In joints of patients with active RA, few…
  • Abstract Number: 1427 • 2015 ACR/ARHP Annual Meeting

    Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia

    Yuki Domon1, Naohisa Arakawa1, Shun-ichi Yasuda2, Kensuke Saeki2, Mayumi Kano2, Masami Kato2 and Yutaka Kitano1, 1Biological Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan, 2Hashima Laboratory, Nihon Bioresearch Inc., Gifu, Japan

    Background/Purpose: Mirogabalin (DS-5565) is a novel ligand of the α2δ subunit of voltage-gated calcium channels. Mirogabalin possesses unique binding characteristics to α2δ subunits, and potent…
  • Abstract Number: 2563 • 2015 ACR/ARHP Annual Meeting

    Immune Regulation By Migrating Mesenchymal Stem Cells Ameliorate Inflammatory Arthritis in Mice

    Seung Min Jung, Yoojun Nam and Ji Hyeon Ju, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Mesenchymal stem cells (MSCs) function as immune regulators in inflammatory conditions. However, it is unclear how to control local inflammation by systemically administered MSCs. We…
  • Abstract Number: 1435 • 2015 ACR/ARHP Annual Meeting

    Central Pain Sensitization in Rheumatoid Arthritis – Role of ACPA?

    Katarzyna Rogoz1, Teresa Fernandez Zafra1, Catia Cerqueira2, Per Johan Jakobsson3, Katalin Sandor4, Erwan Le Maître5, Magnus LA. Andersson6, K. Lundberg7, Camilla Svensson4 and Jon Lampa8, 1Physiology and pharmacology, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 5Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Dep of Neurology, Karolinska Institute, Stockholm, Sweden, 7Karolinska Institute, Stockholm, Sweden, 8Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Chronic pain continues to be a significant problem for patients with rheumatoid arthritis (RA), even when the disease is medically controlled or in remission.…
  • Abstract Number: 2564 • 2015 ACR/ARHP Annual Meeting

    Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis

    Jackeline Araujo, Cullen Lilley and Kimberlee Mix, Biological Sciences, Loyola University New Orleans, New Orleans, LA

    Background/Purpose: The orphan nuclear receptor 4A2 (NR4A2 / NURR1) is emerging as a critical transcription factor in chronic inflammatory joint diseases. We have demonstrated elevated…
  • Abstract Number: 1575 • 2015 ACR/ARHP Annual Meeting

    Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis

    Ruth Davies1, Daniela Iacono2, Lauren A. Jordan1, Jessica O Williams1, Charlotte Rawlings1, Derek Lang3, Anwen S. Williams1 and Ernest H. Choy1, 1Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, 2Department of Clinical and Experimental Medicine. Rheumatology Section. Second University of Naples, Naples, Italy, 3Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose:  Mortality is increased in Rheumatoid arthritis (RA) patients mainly due to cardiovascular (CV) disease; however the biologic mechanisms are unknown. Increased CV risk in…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology